文献速递乳腺癌放疗

乳腺癌腋窝放疗一周方案与三周方案五年正常组织效应比较:FAST-Forward III期试验腋窝亚组结果

Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study.
PubMed 文献 · Radiother Oncol · 2025-05-04

FAST-Forward腋窝亚组随机对照试验比较26 Gy/5次/1周与40 Gy/15次/3周腋窝放疗,469例患者入组,主要终点为五年患者报告的中重度手臂或手肿胀,两组发生率分别为11%与10%,差值1%(90%CI -6%,8%, p=0.49),提示一周方案安全。

要点

  • 26 Gy/5次/1周腋窝放疗五年中重度手臂或手肿胀发生率为11%,与40 Gy/15次/3周的10%相近
  • 两组其他手臂和肩部症状相似,均未出现臂丛神经病变
  • 五年患者报告的正常组织效应支持一周大分割方案用于需辅助腋窝放疗的乳腺癌患者

核心结论

  • 五年患者报告的正常组织效应表明26 Gy/5次/1周大分割方案对需要辅助腋窝放疗的乳腺癌患者是安全的。

研究设计与样本

  • 随机、非劣效、非盲法亚组研究(ISRCTN19906132),纳入50家英国中心的469例患者。
  • 患者为侵袭性乳腺癌(pT1-3, pN1-3a, M0)术后需腋窝放疗(任何或全部1-4站),随机接受40 Gy/15次(对照组)、26 Gy/5次或27 Gy/5次(一周方案)。
  • 27 Gy/5次组因三年主要试验正常组织效应结果提前关闭;本分析聚焦26 Gy/5次与对照组的比较。
  • 主要终点为五年患者报告中重度手臂或手肿胀,旨在排除10%的增加(假设对照组发生率10%;90%把握度,单侧α=0.05,每组n=172)。

主要发现

  • 完成五年问卷者中,40 Gy/15次组11/107(10%)和26 Gy/5次组13/116(11%)报告中重度手臂或手肿胀,差值1%(90%CI -6%, 8%, p=0.49)。
  • 两组其他手臂和肩部症状相似,均无臂丛神经病变病例。

关键数值与推荐

  • 主要终点界值为排除10%的增加(假设对照组发生率10%),实际差值1%(90%CI -6%, 8%, p=0.49)。

临床怎么用

  • 对于需要辅助腋窝放疗的乳腺癌患者,可考虑采用26 Gy/5次/1周大分割方案。

局限性

  • 27 Gy/5次组提前关闭,本分析仅比较26 Gy/5次与对照组。
  • 非盲法设计。
  • 五年问卷完成者样本量小于随机分组总人数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: FAST-Forward showed that 26 Gray (Gy) in 5 fractions (Fr) over one week adjuvant radiotherapy to breast or chest wall was as safe and effective as a three-week schedule (40 Gy/15Fr) for early breast cancer. The nodal sub-study investigated whether a one-week schedule is safe for adjuvant axillary radiotherapy. MATERIALS AND METHODS: In this randomised, non-inferiority, non-blinded sub-study (ISRCTN19906132), patients with invasive breast cancer (pT1-3, pN1-3a, M0) following surgery requiring axillary radiotherapy (any or all levels 1-4) were randomised to 40 Gy/15Fr (three weeks, control), 26 Gy/5Fr or 27 Gy/5Fr (one week) atlas-based radiotherapy planning, including quality assurance. The 27 Gy/5Fr group closed early due to three-year main trial normal tissue effects suggesting 26 Gy/5Fr would be optimal; this analysis focusses on comparison between 26 Gy/5Fr and control. Primary endpoint was five-year patient-reported moderate or marked arm or hand swelling, aiming to exclude a 10 % increase (assuming 10 % incidence with control; 90 % power, one-sided α = 0.05, n = 172 per group). RESULTS: 469 patients were randomised from 50 UK centres (182 40 Gy/15Fr, 183 26 Gy/5Fr, 104 27 Gy/5Fr). Median age 61 years; 250 (54 %) and 182 (39 %) had grade 2 and 3 tumours respectively; 261 (56 %) had axillary dissection. Of those who completed a five-year questionnaire, 11/107 (10 %) 40 Gy/15Fr and 13/116 (11 %) 26 Gy/5Fr reported moderate or marked arm or hand swelling, difference 1 % (90 % confidence interval -6%, 8 %, p = 0.49). Other arm and shoulder symptoms were similar between groups with no cases of brachial plexopathy. CONCLUSION: Five-year patient-reported normal tissue effects suggest 26 Gy/5Fr/1-week hypofractionation is safe for breast cancer patients requiring adjuvant axillary radiotherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Brunt AM, Cafferty FH, Wheatley D, et al. Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study. Radiother Oncol. 2025. PMID: 40379410. doi:10.1016/j.radonc.2025.110915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。